Magazine article Clinical Psychiatry News

Early Pain Reduction Flags Greater Duloxetine Efficacy

Magazine article Clinical Psychiatry News

Early Pain Reduction Flags Greater Duloxetine Efficacy

Article excerpt

ISTANBUL, TURKEY -- Early marked reduction in pain in response to duloxetine proved to be the strongest predictor of significant long-term improvement in depressive symptoms in depressed subjects in the German PADRE study.

A 50% or greater improvement in self-gauged overall pain symptoms on a visual analog scale (VAS) after 4 weeks on the selective norepinephrine reuptake inhibitor was associated with a threefold greater likelihood of achieving at least a 50% decrease on the clinician-rated Inventory for Depressive Symptomatology (IDS) scale at 6 months, the primary study end point, Dr. Michael Linden said at the annual congress of the European College of Neuropsychopharmacology.

PADRE was a prospective observational study in which 4,517 adult outpatients with a depressive episode received treatment with duloxetine (Cymbalta) at 693 centers in Germany. Lilly Deutschland and Boehringer Ingelheim sponsored the study. The mean age of participants was 52 years, and 72% were women.

The mean baseline score on the clinician-rated IDS was 40 on the 0-84 scale. Eighty percent of subjects had moderate to severe painful symptoms at baseline (VAS score of greater than 30 out of a possible 100). During the 6-month study, 26. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.